LGND240920P100000
- 0.40
- 0.000.00%
Ligand Pharmaceuticals Newsroom
Pulling Back 4.4% This Week, Ligand Pharmaceuticals' NASDAQ:LGND) One-year Decline in Earnings May Be Coming Into Investors Focus
Express News | Ligand Pharmaceuticals - Following Engagement With FDA, Co Expects to Submit an Snda for Potential Modification to Liver-Monitoring Rems
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (Sparsentan), the Only Non-Immunosuppressive Treatment That Significantly Slows Kidney Function Decline in IgA Nephropathy
Express News | Ligand Partner Travere Therapeutics Receives Full FDA Approval for Filspari® (Sparsentan), the Only Non-Immunosuppressive Treatment That Significantly Slows Kidney Function Decline in Iga Nephropathy
Travere Gains on Full FDA Approval for Kidney Drug Filspari
Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
Small-cap and Mid-cap Health Care Has Room to Rally - Roth MKM
Looking Into Ligand Pharmaceuticals's Recent Short Interest
Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings
Private Capital's Strategic Moves Highlight Ligand Pharmaceuticals in Q2 2024
Ligand Pharmaceuticals Insider Sold Shares Worth $1,797,133, According to a Recent SEC Filing
Ligand Pharmaceuticals Is Maintained at Buy by Benchmark
Ligand Pharmaceuticals Price Target Raised to $110.00/Share From $95.00 by Benchmark
Roth MKM Says Small-Cap Value Reaches Key Technical Support, Lists 14 "Bullish" Stocks
CEO & Director of Ligand Pharmaceuticals Todd Davis Buys 3.3% More Shares
Express News | Ligand Pharmaceuticals Inc : Benchmark Raises Target Price to $110
Insider Buying: CEO Todd Davis Acquires Shares of Ligand Pharmaceuticals Inc (LGND)
Ligand Pharmaceuticals Price Target Maintained With a $144.00/Share by HC Wainwright & Co.
10-Q: Q2 2024 Earnings Report
RBC Capital Reiterates Outperform on Ligand Pharmaceuticals, Maintains $130 Price Target